Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2023 Sep 10:2023.09.08.23295280.
doi: 10.1101/2023.09.08.23295280.

Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021-2022: an analysis of real-world data

Alvaro Alonso  1 , Alanna A Morris  2 , Ashley I Naimi  1 , Aniqa B Alam  1 , Linzi Li  1 , Vinita Subramanya  1 , Lin Yee Chen  3 , Pamela L Lutsey  4
Affiliations

Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021-2022: an analysis of real-world data

Alvaro Alonso et al. medRxiv. .

Update in

Abstract

Objective: To evaluate utilization of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and angiotensin receptor neprilysin inhibitors (ARNi) in patients with atrial fibrillation (AF) and heart failure (HF).

Methods: We analyzed the MarketScan databases for the period 1/1/2021 to 6/30/2022. Validated algorithms were used to identify patients with AF and HF, and to classify patients into HF with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). We assessed the prevalence of SGLT2i and ARNi use overall and by HF type. Additionally, we explored correlates of lower utilization, including demographics and comorbidities.

Results: The study population included 60,927 patients (mean age 75, 43% female) diagnosed with AF and HF (85% with HFpEF, 15% with HFrEF). Prevalence of ARNi use was 11% overall (30% in HFrEF, 8% in HFpEF), while the corresponding figure was 6% for SGLT2i (13% in HFrEF, 5% in HFpEF). Use of both medications increased over the study period: ARNi from 9% to 12% (from 22% to 29% in HFrEF, from 6% to 8% in HFpEF), and SGLT2i from 3% to 9% (from 6% to 16% in HFrEF, from 2% to 7% in HFpEF). Female sex, older age, and specific comorbidities were associated with lower utilization of these two medication types overall and by HF type.

Conclusion: Use of ARNi and SGLT2i in patients with AF and HF is suboptimal, particularly among females and older individuals, though utilization is increasing. These results underscore the need for understanding reasons for these disparities and developing interventions to improve adoption of evidence-based therapies among patients with comorbid AF and HF.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Prevalence of sodium-glucose cotransporter-2 inhibitors and angiotensin receptor-neprilysin inhibitor use among patients with atrial fibrillation and heart failure by quarter, MarketScan databases 2021–2022. ARNi: angiotensin receptor-neprilysin inhibitor; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; SGLT2i: sodiumglucose cotransporter-2 inhibitor.
Figure 2.
Figure 2.
Prevalence of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter-2 inhibitor use among patients with atrial fibrillation and heart failure by age and sex, MarketScan databases 2021–2022. ARNi: angiotensin receptor-neprilysin inhibitor; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; SGLT2i: sodium-glucose cotransporter-2 inhibitor.
Figure 3.
Figure 3.
Prevalence of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter-2 inhibitor use among patients with atrial fibrillation and heart failure by presence of comorbidities and use of other relevant medications, MarketScan databases 2021–2022. ARNi: angiotensin receptor-neprilysin inhibitor; CAD: coronary artery disease; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; MRA: mineralocorticoid receptor antagonist; SGLT2i: sodium-glucose cotransporter-2 inhibitor.
See this image and copyright information in PMC

References

    1. Al-Khatib SM, Benjamin EJ, Albert CM, Alonso A, Chauhan C, Chen PS, Curtis AB, Desvigne-Nickens P, Ho JE, Lam CSP, et al. Advancing research on the complex interrelations between atrial fibrillation and heart failure: a report from a US National Heart, Lung, and Blood Institute virtual workshop. Circulation. 2020;141:1915–1926. - PMC - PubMed
    1. Cherian TS, Shrader P, Fonarow GC, Allen LA, Piccini JP, Peterson ED, Thomas L, Kowey PR, Gersh BJ, Mahaffey KW. Effect of atrial fibrillation on mortality, stroke risk, and quality-of-life scores in patients with heart failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). Am J Cardiol. 2017;119:1763–1769. - PubMed
    1. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91:2d–8d. - PubMed
    1. Karnik AA, Gopal DM, Ko D, Benjamin EJ, Helm RH. Epidemiology of atrial fibrillation and heart failure: a growing and important problem. Cardiol Clin. 2019;37:119–129. - PubMed
    1. Claxton JS, Chamberlain AM, Lutsey PL, Chen LY, MacLehose RF, Bengtson LGS, Alonso A. Association of multimorbidity with cardiovascular endpoints and treatment effectiveness in patients 75 years and older with atrial fibrillation. Am J Med. 2020:S0002–9343(0020)30344-30342. - PMC - PubMed

Publication types